Addressing screams for evidence on renoprotection by GLP-1 receptor agonists

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database

(2021) Hajime Nagasu et al.   DIABETES CARE

GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes

(2021) Yang Xu et al.   KIDNEY INTERNATIONAL

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

(2021) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

(2020) Björn Pasternak et al.   DIABETES CARE

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases

(2020) Yan Xie et al.   DIABETES CARE

Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.

(2020) Kohjiro Ueki et al.   KIDNEY INTERNATIONAL

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

(2019) Hiddo J L Heerspink et al.   Lancet Diabetes & Endocrinology